E for L Aim Public Co., Ltd. · SET:EFORL
E for L Aim Public — FY2015 Earnings Presentation
29 slides from E for L Aim Public's earnings presentation, Mar 31, 2016
Slide 1: E For L Aim Public Company Limited
E FOR L AIM PUBLIC COMPANY LIMITED March 31, 2016
Slide 2: Financial Highlight
FINANCIAL HIGH LIGHT Mar 08, 2016 Paid-Up Capital (THB Million) 690.0 Par Value (THB/share) 0.075 Dividend Payout (%) >40% Free Float (%) 79.30% Book Value (THB/share) 0.14 Stock data 26-Week Range (THB) 1.17/0.50 Sector MAI P/E (x) 31.05 P/BV (x) 5.00 2
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by EFORL AIM PUBLIC COMPANY LIMITED (“EFORL”) and is circulated for the purpose of general information only, it is not intended for any specific person or purpose and does not constitute a recommendation regarding the securities of EFORL. No warranty (e
Slide 4: Glossary
GLOSSARY EFORL E for L Aim Public Company Limited SPACEMED Spacemed Co., Ltd. SIAM SNAIL Siam Snail Co., Ltd. THAT’SO That’so Asia Corporation Co., Ltd. WCI Wuttisak Cosmetic Inter Co., Ltd. WCIG Wuttisak Clinic Intergroup Co., Ltd. WCIH WCI Holding Co., Ltd. WGI Wuttisak Grand Inter Co., Ltd. WPI W
Slide 5: EFORL Group Overview
EFORL GROUP OVERVIEW 5
Slide 6: EFORL History
Purchased 51% of Siam Snail Co., Ltd., which has the formal and solely license to produce/operate the EFORL HISTORY special and concentric filtrate of snails from Chulalongkorn University Intellectual Property Institute (see www.cuipi.chula.ac.th. ) in June. Increase Siam Snail Co., Ltd. registe
Slide 7: Recent developments and milestones
Mar.30, 2016: Siam Snail had planned for a Grand Opening Snail semi-natural farm at The Eastern Outskirt of Bangkok. Feb.3, 2016: WCIH was appointed to Maybank KimEng Securities (Thailand) Plc. And CIMB Securities (Thailand) Co., Ltd. to be the Financial Advisory (FA) for funding and to be a lis
Slide 8: EFORL Group structure
EFORL GROUP Updated as of October 2015 100% 50.17% 51% 18% Spacemed WCIH Spacemed Co., Ltd. WCI Holding Co., Ltd. Siam Snail Co., Ltd. That’s so Asia Corporation Co., Ltd. 100% Wuttisak Clinic Inter Group Co., Ltd. 99.97% 99.99% 99.97% 99.98% WCI WPI WGI WSS Wuttisak Cosmetic Wuttisak Pharmacy Wutti
Slide 9: Revenue by business segment
Revenue (MB.)** 62% Y2015 Y2014 EFORL 1,911 1,181 MEDICAL Revenue (MB.)** EQUIPMENT Y2015 Y2014 211% SPACEMED 4,504 1,450 EFORL BEAUTY GROUP CLINIC WCIG Revenue (MB.)** SIAM SNAIL Y2015 Y2014 837% COSMETIC 2,587 276 WCI 9 **See Page No.63, EFORL AUDITED REPORT 2015 Thai Version
Slide 10: Industry Overview
INDUSTRY OVERVIEW 10
Slide 11: Forecast GDP Growth
FORECAST GDP GROWTH 2014 2015F1 2016F1 2015F2 2016F2 2015F3 2016F3 Sources : 1/ Bank of Thailand 2/ World Bank GDP 0.9 3.0 4.1 3.5 4.0 2.5 3.3 3/ CIMB THAI, Research Office (Oct.6, 2015) 11 Sources : World Bank, retrieved date Oct.08, 2015.
Slide 12: Health Care Industry Overview: Linkage with GDP plus the Aging Society Trend
HEALTH CARE INDUSTRY OVERVIEW: LINKAGE WITH GDP PLUS THE AGING SOCIETY TREND Electricity Gas & Water Supply 9% Hotel & Restaurants 10% Public Admins & Social Security 6% Healthcare 4% Wholesale & Retail 35% Transportation 25% Education 6% Others 5% Healthcare industry accounts for
Slide 13: Key Findings
KEY FINDINGS Health expense is directly linked with country’s GDP. The amount per person on health care spending substantially surges in the middle class. Likewise, the inevitable rise in aging people will directly affect the health industry due to the transition shift in structural changes. H
Slide 14: Growth Drivers
GROWTH DRIVERS Healthcare industry possesses a positive outlook given the aging society, coming AEC consolidation, Thailand pinned as a medical hub, and strong growth of medical tourism. Aging Society: The inevitably rising population has led to substantial increase in health care spending. Thailand
Slide 15: Country Healthcare Industry Compared to GDP
COUNTRY HEALTHCARE INDUSTRY COMPARED TO GDP Given much-lower-than-average health spending compared to GDP, Thai market’s healthcare industry still has big room for rapid growth. 15 The healthcare industry has a big room to growth compared to the world average. Assuming the health expenditure per GDP
Slide 16: EFORL's Product Range
EFORL’S PRODUCT RANGE • IMPORTED MEDICAL DEVICE BY TYPE (THB MILLION) 2010 2011 2012 3 Yr- CAGR (%) General Supply 9,407 11,363 14,555 24% Diagnostic & Therapeutic Equipment for internal medicine 8,075 10,051 11,327 18% Diagnostic imaging and radiotherapy 3,751 4,067 6,180 28% Orthopedic, orthosis a
Slide 17: Company Overview
COMPANY OVERVIEW 17
Slide 18: Turnaround Reward and Research-Covered Reward from MAI
A Company Turnaround Reward (2013) and Research-Covered Reward (2014) from MAI 18
Slide 19: Financial Information
FINANCIAL INFORMATION 19
Slide 20: Financial Data: Statement of Financial Position
FINANCIAL DATA Statement of Financial Position (MB.) Year End of 2015 Year End of 2014 Year End of 2013 Cash 122.46 339.44 641.26 A/R Net 711.25 488.25 65.69 Inventories 726.76 553.52 103.52 Current Assets 1,619.40 1,605.53 815.57 PP&E Net 921.91 1,028.37 15.44 Total Assets 7,305.49 7,366.28 840.99
Slide 21: Financial Data: Statement of Comprehensive Income
FINANCIAL DATA Statement of Comprehensive Income (MB.) Year 2015 Year 2014 Year 2013 Sales 4,503.93 1,450.25 158.23 Other Income 26.10 39.96 12.54 Total Revenues 4,530.03 1,490.21 170.76 COGs 3,212.52 942.71 103.58 SG&A 726.40 241.68 32.81 Total Expenses 3,938.92 1,184.40 142.59 EBITDA 843.23 339.50
Slide 22: Financial Data: Statement of Cash Flow
FINANCIAL DATA Statement of Cash Flow (MB.) Year 2015 Year 2014 Year 2013 Opening Cash Flow 74.95 (122.60) 0.25 Investing Cash Flow 865.90 (3,646.53) (4.44) Financing Cash Flow (1,157.83) 3,467.30 635.96 Net Cash Flow (216.98) (301.82) 631.77 22
Slide 23: Financial Data: Ratios
FINANCIAL DATA Ratios Year 2015 Year 2014 Year 2013 Current Ratio (X) 0.63 0.66 5.77 ROE (%) 18.75 29.42 7.26 ROA (%) 8.06 7.45 6.25 D/E (X) 3.30 5.77 0.21 Total Asset Turnover (X) 0.62 0.36 0.38 Gross Profit Margin (%) 28.67 35.00 34.54 EBIT Margin (%) 13.05 20.52 16.50 Net Profit Margin (%) 4.64 1
Slide 24: Financial Data: Growth Rate
FINANCIAL DATA Growth Rate (%) Year 2015 Year 2014 Year 2013 Sales Growth 210.56 816.56 104.14 COGs Growth 240.77 810.16 35.95 Total Revenue Growth 203.99 772.67 95.82 Total Expense Growth 232.57 730.64 (5.86) Net Profit Growth (12.60) 809.89 N/A 24
Slide 25: Financial Data: Cash Cycle
FINANCIAL DATA Cash Cycle Year 2015 Year 2014 Year 2013 A/R Turnover (Times) 7.51 5.24 4.17 Avg. Collection Period (Days) 48.60 69.71 87.49 Inventory Turnover (Times) 5.02 2.87 1.00 Avg. Inventory Period (Days) 72.73 127.2 364.81 A/P Turnover (Times) 5.78 3.22 1.29 Avg. Payment Period (Days) 63.15 1
Slide 26: Wuttisak History
WUTTISAK HISTORY Added competitive advantage from EFORL’s access to advanced medical equipment for use in treatments. Exclusive rights for the commercialization of secretion from Siam Snail Co., Ltd.. Established WCIH in November. EFORL and founders buy out WCIG from A Foreign investment fun
Slide 27: Wuttisak Clinic Inter Group Co., Ltd. and the Subsidiaries
WUTTISAK CLINIC INTER GROUP CO., LTD. AND THE SUBSIDIARIES. 27
Slide 28: Twelve Branches in CLMV
TWELVE BRANCHES IN CLMV* Two branches in Myanmar Four branches in Laos Rangoon (2) (LPDR) Vientiane (1) Pakse (1) Savannakhet (1) Luang Prabang (1) Four branches in Cambodia 120 branches spread Phnom Penh (3) Siem Reap (1) thorough The Kingdom of Thailand Bangkok and outskirt 54 Two
Slide 29: Thank you
E 4 L Aim Thank you
E for L Aim Public Company — FY2015 Earnings Presentation on 6ix